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39 Does low frequency ventilation (LFV) during cardiopulmonary bypass (CPB) improve 
40 inflammatory markers and lung function compared to both lungs left collapsed in patients 
41 undergoing CABG?
42 Key findings
43 There were no significant differences between groups in inflammatory markers measured in the 
44 lung tissue and blood.
45 Take-home message
46 LFV during CPB when compared to both lungs left collapsed does not reduce inflammation in 




















































































68 Glossary of Abbreviations
69 Low frequency ventilation (LFV) 
70 Cardiopulmonary bypass (CPB) 
71 Coronary artery bypass grafting (CABG) 
72 Acute lung injury (ALI)
73 Adult respiratory distress syndrome (ARDS)
74 Positive end-expiratory pressure (PEEP)
75 cardioplegic arrest (CA)
76 Pulmonary function tests (PFTs)
77 Respiratory index [(PAO2-PaO2)
78 Forced vital capacity (FVC)
79  Forced vital capacity ratio (FVCR)
80 forced expiratory volume in one second (FEV1)
81 Forced expiratory volume after one second (FEV1) 
82 Continuous positive airway pressure (CPAP) 
83 Geometric means (GM).
84 Means and standard deviations (SDs)
85 Ventilation/perfusion distribution (V/Q)
86 Adenine nucleotides (ATP, ADP, AMP)
87 Conventional mechanical ventilation (CV) 
88 Open Lung Concept (OLC)
89 Partial pressure of oxygen (pO2) (paO2)
90 Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-B)

































































93 Objective: Pulmonary dysfunction is a common complication in patients undergoing heart 
94 surgery. Current clinical practice does not include any specific strategy for lung protection.  To 
95 compare the anti-inflammatory effects of low frequency ventilation (LFV), as measured by NF-κB 
96 p65 pathway activation, for the entire cardiopulmonary bypass (CPB) versus both lungs left 
97 collapsed in patients undergoing coronary artery bypass grafting (CABG) 
98 Methods: Two group parallel randomised controlled trial. Primary outcome was inflammation 
99 measured by NF-B p65 activation in pre- and post-CPB lung biopsies. Secondary outcomes were 
100 additional inflammatory markers in both biopsy tissue and blood. 
101 Results: 37 patients were randomly allocated to LFV (18) and to both lungs left collapsed (19). 
102 The mean concentration of NF-κB p65 in the biopsies before chest closure (adjusted for pre-CPB 
103 concentration) was higher in the LFV group compared to both lungs left collapsed group but this 
104 was not significant (0.102, 95% CI -0.022 to 0.226, p=0.104). There were no significant 
105 differences between groups in the other inflammatory markers measured in tissue and blood.
106 Conclusions: In patients undergoing elective CABG, the use of LFV during CPB when compared 
107 to both lungs left collapsed does not seem to reduce inflammation in lung biopsies and blood.  
108 Abstract words count: 202
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115 Pulmonary dysfunction is a common complication for patients after cardiac surgery using 
116 cardiopulmonary bypass (CPB) [1]. Severity ranges from mild atelectasis to life threatening acute 
117 lung injury (ALI) or respiratory failure requiring prolonged postoperative ventilation [2] or adult 
118 respiratory distress syndrome (ARDS) [3-5].  Harmful effects of CPB on pulmonary function 
119 persist despite advances in anaesthetic techniques [6]. Pulmonary dysfunction after cardiac 
120 surgery also affects clinical outcomes with increasing morbidity, mortality and delaying discharge 
121 from hospital, leading to increase in the health care resources used and their associated cost [3, 7-
122 13]
123 Presumed causative factors for atelectasis and ALI, include inflammation, prolonged lung 
124 collapse, pulmonary ischemia and related reperfusion injury, blood contact with the surface of the 
125 heart-lung machine, endotoxemia, surgical trauma, blood loss and transfusion [14, 15]. 
126 Inflammatory activation and cytokine release have been correlated with outcome after cardiac 
127 surgery [16]. Pulmonary function 24 hrs after CPB is associated with raised plasma levels of 
128 inflammatory cytokines and reduced levels of anti-inflammatory cytokines [17]. The 
129 inflammatory response from the lung during CPB and mechanical ventilation originates at the 
130 alveolar membrane as a result of collapse, ischemia, reperfusion injury and mechanical stress [18-
131 20]. Suppression of activation of inflammatory mediators during CPB is associated with a 
132 reduction in pulmonary dysfunction [21]. 
133 Current clinical practice does not include any specific strategy for lung protection during CPB.  
134 When CPB is started, often both lungs are left collapsed for the entire CPB duration. We recently 
135 provided evidence in an experimental pig model that low frequency ventilation (LFV) during CPB 
136 reduces post-CPB lung injury [22].
137 Here, we report an evaluation of the effect of ventilating the lungs at low frequency during CPB 
138 comparing to collapsing the lungs in patients having coronary artery bypass graft surgery (CABG) 
139 with respect to inflammation measured by NF-κB p65 pathway activation and post-operative 
140 pulmonary dysfunction. We used a primary outcome measure that would give an early indication 
141 of inflammatory changes in the lungs and would allow detection of a large effect in a relatively 
142 small trial.
143
144 Materials and Methods
145 This study was a single-centre, two-group parallel randomised controlled trial. Patients were 
146 randomly assigned in a 1:1 ratio, using a secure concealed internet-based randomisation system 
147 (Sealed EnvelopeTM, https://www.sealedenvelope.com/). Cohort minimisation was used to achieve 
148 balance between groups with respect to baseline lung function (≥60% predicted FEV1). Patients 
149 returned to hospital for a follow up visit 6-8 weeks following the operation. 
150 Study period between 07 January 2013 to 27 June 2014. Trial registration ISRCTN-34428459, 
151 protocol approved by the NRES London- Camden and Islington (REC-12/LO/0458). Protocol 
152 published at http://www.isrctn.com/ISRCTN34428459.
153 Trial Population
154 Patients having elective or urgent CABG with CPB and cardioplegic arrest (CA) at the 
155 Hammersmith Hospital. ( Table 1)
































































157  Age ≥40 and <85 years 




162  Previous pulmonary embolism requiring long term warfarin for ≥3 months
163  Previous cardiac surgery
164  Current congestive heart failure (NYHA class IV)
165  Chronic renal failure 
166  Emergency or salvage operation
167  On corticosteroid or immunosuppressive treatment
168  Severe chronic obstructive pulmonary disease, lung pathology, previous radiotherapy, 
169  Body mass index >35
170
171 Ventilation Protocol
172 Before starting CPB, for all participants, the lungs were ventilated with a tidal volume of 6-8 
173 ml.kg-1, I:E ratio of 1:2, positive end-expiratory pressure (PEEP) of 5cm H2O and FiO2 of 0.5 (range 
174 0.45-0.55 O2).  The ventilatory rate was set to keep the PaCO2 between 4.5 and 5.5 kPa.
175 In the comparator group (both lungs left collapsed), at the onset of CPB the lungs were disconnected 
176 from the ventilator and allowed to collapse completely for the duration of CPB. 
177 In the treatment group (low frequency ventilation, LFV), the respiratory rate was maintained 
178 during CPB at 5 bpm with (FiO2  0.25). PEEP was turned off during LFV but the tidal volume 
179 and inspiration to expiration (I:E) ratio were maintained at 6-8 ml.kg-1 and 1:2. At the end of the 
180 CPB, patients in both groups had a lung recruitment manoeuvre using an FiO2 of 0.5 and holding 
181 the lungs inflated for 15sec at 30cm H2O, before the lungs were reconnected to the ventilator.  The 
182 recruitment manoeuvre was repeated if necessary, though this event was not recorded on the data. 
183 No other variation in ventilation was permitted or necessary. The same ventilator protocol was 
184 used after CPB as before CPB with a PaO2/FiO2 >50 required on first post-bypass gas (i.e. 
185 PaO2>25kPa). If PaO2/FiO2 <50 then the recruitment manoeuvre was repeated.  
186 Anaesthetic protocol
187 Following premedication with temazepam (dose 20-30mg), anaesthesia was induced with 
188 propofol and remifentanil, using pancuronium 0.1 mg/kg for muscle relaxation. This was 
189 maintained by infusion of propofol and remifentanil (5mg remifentanil to 1g propofol), with 
190 isoflurane if required to keep the entropy value of the processed EEG below 55. At chest closure, 
191 7g/kg fentanyl was given in combination with plain propofol, which was switched to a 
192 propofol/remifentanil mixture for the transfer to the cardiac intensive care unit. It is important to 
193 mention that mixing remifentanil in propofol was at the time of our study common practice and 
194 was used in every subject of both groups. O'Connor's work [23] was published shortly after 
195 recruitment to our study had finished, and in any case may not be relevant because our syringes 
196 were kept horizontal throughout the procedure. 
197
































































199 A standard CPB was used, primed with 1400 ml of Hartmann’s solution and 10000 IU of heparin. 
200 Systemic temperature was between 32°C and 35°C.  Cardioplegic arrest was achieved with 
201 intermittent antegrade cold blood cardioplegia.
202 Lung biopsy protocol
203 To measure inflammatory markers in the lung, two lung biopsies (1cm x 1cm) were taken using 
204 the LigaSure Impact™ instrument (LF4318, Covidien, Minneapolis, USA).  The first (pre-CPB) 
205 biopsy was taken from the left upper lobe immediately after sternotomy and the second from the 
206 left lower lobe prior to weaning from CPB after lung recruitment manoeuvre (see above). 
207 The criteria for extubation were: Normothermia (a core temperature range of 36.0°C to 37.0°C); 
208 haemodynamical stability and blood loss <50mls/h; comfortable breathing with good bilateral air 
209 entry (RR 10-20/min, tidal volumes 8-10mls/kg, minimal tracheal suction) and arterial blood 
210 gases with parameters PaO2 >10kpa on FiO2 <0.5, PCO2<7 kPa, BE -5 to +5. 
211 Blood samples were taken: i) after anaesthetic induction and pre-sternotomy, ii) 10 minutes after 
212 the end of CPB, and iii) 2, 6 and 24 hours after the end of CPB.  No blood sample were taken 
213 during CBP as our end points was to look into the effect before and after CPB.
214 Outcomes 
215 The primary outcome was inflammation measured by NF-B p65 activation in pre- and post-CPB 
216 lung biopsies.  This outcome measure was chosen because exposure of a cell to a cytokine or an 
217 infectious agent leads to binding to a cell surface receptor and activation of a kinase cascade 
218 resulting in the nuclear translocation of the master pro-inflammatory transcription factor NF-B. 
219 NF-B is known to drive the expression of most inflammatory genes [24, 25]. 
220 Secondary outcomes included additional inflammatory markers in both biopsy tissue and blood. 
221 Namely, p38 MAPK phosphorylation, expression of TNF, IL1, IL18, IL6, IP10, IL8, IL10, 
222 chemokine receptor CXCR3 and Caspase 3 measurements of apoptosis in biopsies. ROS levels, 
223 phosphorylation of p38 and NF-κB p65 in blood.
224 Laboratory analysis 
225 Blood samples were taken: i) after anaesthetic induction and pre-sternotomy, ii) 10 minutes after 
226 the end of CPB, and iii) 2, 6 and 24 hours after the end of CPB. 
227 Leukocytes were fixed and lysed with BD Phosflow Lyse /Fix buffer, (BD Biosciences, Oxford, 
228 UK). Samples were stained using a redox-sensitive fluorescent probe 3'-(p-aminophenyl) and 
229 stained with antibodies raised against phosphorylated p38 (Thr180/Tyr182) (Cell Signaling 
230 ♯6908, Danvers, MA, USA) and NF-κB p65 (Ser529) (Cell Signaling ♯4887). Samples were 
231 analysed by flow cytometry compared to unstained controls. 
232
233 Biopsies:
234 The pre-CPB biopsy provided a within-subject control for the second, post-CPB biopsy. 
235 NF-B p65 nuclear localization and activation was assessed by immunofluorescent staining 
236 followed by confocal microscopy and by testing nuclear lysates by DNA-binding ELISA 
237 (TransAm Assay, Carlsbad, USA). 
238 Measurements of p38 MAPK phosphorylation in biopsies were carried out using Western blotting 
239 and were analysed and expressed as ratio of phosphorylated p38 and total p38. Expression of 































































240 TNF, IL-1, IL-18, IL-6, IP-10, IL-8, IL-10 and chemokine receptor CXCR3 were done using 
241 ELISA and qPCR. 
242 For RNA extraction biopsies were homogenised in RLT buffer (Qiagen, Hilden, Germany), 
243 containing beta mercaptoethanol (Sigma-Aldrich, St Louis, USA). RNA was quantified using 
244 nanodrop and reverse transcribed to (ThermoFisher Scientific, Waltham, USA). 
245 Gene expression was measured using Taqman qPCR and normalised to 18S rRNA using the ΔΔct 
246 method.
247 For protein extraction biopsies were homogenised in either radioimmunoprecipitation assay 
248 (RIPA) (Sigma Aldrich) buffer or Lysis buffer AM1 (Active Motif). 
249 Protein concentration was determined using the bicinchoninic acid assay (ThermoFisher 
250 Scientific). ELISA was used to measure expression of TNF, IL-1,IL-18, IL-6, IP-10, CXCL-8, 
251 and IL-10 in the cytoplasmic fraction. Caspase 3 activity was measured by colormetric assay kit 
252 (Abcam, Cambridge, UK), p38 phosphorylation by ELISA and Western Blot [26].
253 Other secondary outcomes included pulmonary function tests (PFTs), pulmonary gas exchange 
254 and adverse events
255 Pulmonary gas exchange was assessed by the respiratory index [(PAO2-PaO2) / (PaO2)] measured 
256 i) post-induction and pre-sternotomy, ii) 10 minutes following CPB weaning, iii) 2 hours post 
257 CPB, iv) 4 hours post CPB, v) first gas post extubation, vi) 12 hours post CPB, and vii) before 
258 removal of the arterial line.   
259 Pulmonary function tests (PFTs) were carried out pre-operatively and at 6-8 weeks post-surgery. 
260 PFTs included forced vital capacity (FVC), forced vital capacity ratio (FVCR), forced expiratory 
261 volume in one second (FEV1), forced expiratory volume after one second (FEV1) and FEV to 
262 FEV1 ratio.  Pulmonary function was assessed by a combination of the following tests: 
263 spirometry, gas diffusion and thoracic gas volume. 
264 During hospital stay and at the follow up visit patients underwent a pulmonary function test and 




269 Without taking the baseline biopsy into account, it was calculated that a sample size of 32 patients 
270 would be able to detect a standardised difference of 1.0 with 80% power and 5% significance (2-
271 tailed).  If the baseline biopsy improves the relative efficiency of the comparison (with an 
272 estimated correlation of 0.5 between measures of the primary outcome for the pre/upper lobe and 
273 post/lower lobe), the trial either had more power (88%) or was able to detect a smaller target 
274 difference (0.9SD). These standardised differences (1.0 or 0.9) represent large differences 
275 between groups; we justified the plausibility of this large target difference on the grounds that the 
276 primary outcome was chosen to assess the biomarker and site (i.e. the lungs) which we 
277 hypothesised would be most directly influenced by the intervention. 
278 This target sample size was able to detect a standardised difference of 0.75 in biomarkers 
279 measured in the serum with 80% power and 5% significance (2-tailed), assuming a correlation of 































































280 0.5 between pre and post-intervention measures and a correlation of 0.7 between the four repeated 
281 post-intervention measures. 
282 The study was not powered to detect differences between the groups in pulmonary function or 
283 adverse events.  Specific adverse events were too infrequent to be able to detect differences 
284 between groups. Frequencies of these adverse outcomes are tabulated, in line with guidelines for 
285 reporting adverse events in trials. The trial was an “early phase” and it aimed at identifying an 
286 intervention worth taking forward to late phase 3 trials quickly and relatively inexpensively, hence 
287 the choice of a primary outcome and an effect size that would allow a small sample size. 
288
289 Primary analyses were by intention-to-treat.  The final analyses were performed after the database 
290 had been locked and the statistical analysis plan approved.  The statistical software STATA 
291 (version 13.2) was used to analyse the data as well as to generate tables, figures, and listings. 
292 Most of the data measured continuously scaled outcomes which are summarised as means and SD, 
293 at each time point if measured more than once, in each treatment group.  If distributions were non-
294 normal, appropriate transformations were used. Analyses were carried out on the transformed data 
295 and the findings were transformed back to the original scale where possible, e.g. if a logarithmic 
296 transformation was used then the results are presented as geometric means (GM). 
297
298 For inflammatory markers in biopsy samples, where only one post-intervention measure was 
299 collected, models were fitted using linear regression to adjust for the baseline level.  Each model 
300 estimated the main effect of group allocation (LFV vs. conventional management) and the 
301 baseline covariate.
302 For inflammatory markers in monocytes and polymorphonuclear cells from peripheral blood 
303 samples and pulmonary gas exchange expressed as A-a gradient, mixed regression models were 
304 fitted. These models estimated coefficients for group allocation and the interaction term for group 
305 allocation by time. If the interaction was significant (p<0.05), then a group comparison is reported 
306 at each time point. All results are presented as differences between, or ratios of, the means for the 




311 Forty-nine patients were eligible and were invited to take part in the trial between January 2013 
312 and June 2014; 38 gave written informed consent, 8 declined for personal reasons and 3 preferred 
313 the standard procedure.  One patient became ineligible (had off-pump CABG) and was withdrawn 
314 (see consort diagram, Fig 1); available data for the remaining 37 patients were analysed (18 in the 
315 LFV group and 19 in both lungs left collapsed CPB group). Baseline characteristics, pre-operative 
316 co-morbidities, operation details and baseline respiratory measurements were balanced (Table 1). 
317 Means and standard deviations (SDs) for all the markers are tabulated in (TableA1 and TableA2). 
318 Adverse events during hospital stay and at follow up are tabulated in (Table 2), Figure 2 illustrates 
319 the treatment effect and (Figure 3) illustrates the raw data on a log scale (for y axis).
320 Primary outcome
321 The mean concentration of NF-κB p65 in the biopsies before chest closure (adjusted for pre-CPB 
322 concentration) was higher in the LFV group compared to both lungs left collapsed CPB group but 































































323 this was not significant (Table A1, Table A2a), (Figure 2a, Figure3a); (0.102, 95% CI -0.022 to 
324 0.226 p=0.104).
325 Secondary outcomes
326 Biopsy markers analysis results are summarised in (Table A2) and (Figure 2a).
327 The mean concentration of p38 MAPK in the biopsies before chest closure (adjusted for pre-CPB 
328 concentration) was lower for the LFV group compared to both lungs left collapsed CPB group but 
329 this was not significant. Expression of IL18 and IL10 were also lower in the LFV group compared 
330 to both lungs left collapsed CPB group but not by statistically significant amounts. 
331 Gene expression of TNFA, IL1B, IL6, IP10, IL8 and CXCR3 as well as caspase activity were 
332 higher in the LFV group compared to the standard CPB group. These differences were statistically 
333 significant for IL1B and IL6. There were no significant differences in cytokine levels between 
334 each group. 
335 Blood markers analysis results are summarised in (Table A1b, Table A2) and (Figure 2b). 
336 Leukocytes were separated into monocytes, granulocytes and lymphocytes by forward and side 
337 scatter. The permeabilised monocytes and granulocytes, when measuring p38 MAPK and NF-κB 
338 p65, showed significant overlap by this method and were therefore treated as a single group. 
339 There were no statistically significant differences in NF- κB, MAPK, ROS, or A-a gradients 
340 between groups. 
341 NF-κB p65 and p38 MAPK levels in combined monocytes and granulocytes were lower in the 
342 LFV group compared to both lungs collapsed CPB group, but these differences were not 
343 statistically significant.  NF-κB p65 levels in lymphocytes were higher in the LFV group 
344 compared to both lungs left collapsed CPB group but not significantly so.  ROS levels were not 
345 significantly lower in all cell types in the LFV group compared to both lungs left collapsed group. 
346 When time was fitted in the model, we found that p38 MAPK in lymphocytes levels were 
347 significantly lower in the LFV group at 2, 6 and 24 hours compared to 10 min. The interaction of 
348 intervention x time was not significant at any time point for any of the blood markers.
349 The A-a gradient was higher in the LFV group compared to both lungs left collapsed CPB group, 
350 but this was not significant Table A3. When time was fitted in the model, we found that there was 
351 a significant reduction in A-a gradient in time compared to 10 min in the LFV group. However, 
352 the interaction of intervention x time was not significant at any time point. No difference was 
353 found in lung functions between the two groups (Table A3b)
354 Frequency of adverse events are summarised in (Table 2).
355 Mask CPAP was necessary for one patient in the LFV group and 2 in both lungs left collapsed 
356 CPB group. Arrhythmia occurred in 50% of patients in the LFV group and 37% of patients in both 
357 lungs left collapsed CPB group. The biggest difference in groups for occurrence of adverse events 
358 was in relation to the need for haemodynamic support, 89% of patients in the LFV group vs 47% 
359 in both lungs left collapsed CPB group. Hospital and post discharge infective complications were 
360 similar between groups. 
361
362 Discussion
363 This trial investigated the possibility of reducing the inflammatory response associated with 
364 CABG by a technique of ventilating of the lungs at low frequency during CPB. The change in 































































365 inflammatory response was measured in both tissue biopsy and blood using NF-κB p65 in lung 
366 biopsies and other inflammatory markers in both tissue and blood. 
367 Our selection for NF-B as a primary end point was because its activation can be induced upon 
368 physical or oxidative stresses resulting from cardiac surgery using CPB [27]. NF-B seems to be a 
369 reasonable end point reflecting the adverse effect of the inflammation on the lungs.  We could 
370 argue that it might not be very specific to lung tissue but rather systemic inflammatory status as it 
371 can be also produced by, physiological changes including ischemia and hyperosmotic shock, or by 
372 numerous inflammatory cytokines and chemokines [27].  Our choice to measure NF-B in the 
373 lung tissue with a control sample as the primary end-point can be justified as CPB enhanced lung 
374 and systemic inflammation. Samples have been collected for future transcriptomic and proteomic 
375 analysis and this may help provide insight into possible pathways driving CPB.
376 Results showed levels of all markers apart from p38 MAPK, IL18 and IL10 measured in the lung 
377 biopsy tissue were higher in the LFV group compared to both lungs left collapsed CPB group. 
378 However only the increases in IL6 and IL1B gene expression were statistically significant and 
379 these differences were counter to our working hypothesis that LFV would reduce inflammation 
380 following surgery. We observed a marked increase in the expression of a number of NF-B-
381 induced inflammatory markers at both the protein and mRNA level in lung tissue following CPB.  
382 The failure to observe any change in NF-B p65 activation in tissue may reflect the rapid early 
383 nature of NF-B activation compared to the time under CPB (in the LFV group median of 71min, 
384 IQR 63.5-93.5 and in both lungs left collapsed group median of 80min, IQR  60-92).  Gene 
385 stimulation can lead to waves of NF-B activation over time [28] and we may have missed a 
386 second round of NF-B activation at the time points analysed chosen.  However, we detected a 
387 marked effect on p38 MAPK activity in both lung tissue and in peripheral blood following CPB 
388 and the effect in blood reached significance over the time series and may have been greater if 
389 subsets of cells were analysed.  It is possible that CPB is a greater activator of inflammation in 
390 response to oxidative stress than NF-B and further studies would be required in disease models 
391 to test this hypothesis. Overall, there was no significant difference in the inflammatory markers 
392 measured in the blood between LFV and both lungs left collapsed CPB group. 
393 A clinical study reported the use of continuous positive airway pressure (CPAP) during CPB in 14 
394 elective cardiac surgery patients. Seven patients received CPAP at 10cm H2O during CPB, and in 
395 the other seven patients, the lungs were open to the atmosphere (control). CPAP at 10cm H2O 
396 resulted in significantly more perfusion of lung areas with a normal ventilation/perfusion 
397 distribution (V/Q) and significantly less shunt and low V/Q perfusion 4h after CPB in comparison 
398 with the control group. The authors concluded that CPAP at 10cm H2O during CPB is a simple 
399 manoeuvre that improves postoperative gas exchange and resulted in significantly more perfusion 
400 of lung areas with a normal ventilation/perfusion distribution (V/Q) and significantly less shunt 
401 [29].
402 The effect of both low frequency ventilation (LFV) and continuous positive airway pressure 
403 (CPAP) during CPB to reduce post-CPB lung injury have been evaluated in an established 
404 experimental pig model  [22]. This study strongly suggested that the use of LFV is associated with 
405 significantly better pulmonary gas exchange, higher adenine nucleotide, lower lactate 
406 dehydrogenase levels and reduced histological damage in lung biopsies as well as lower DNA 
407 levels in bronchoalveolar lavage compared to the control group. The rationale for this 
408 experimental study was to maintain some degree of ventilation during CPB to prevent persisting 
409 lung collapse and complete loss of gas exchange by passive diffusion at the blood–gas barrier. A 
410 similar concept was used by Reis Miranda and colleagues who studied 62 patients post cardiac 































































411 surgery, randomly assigned to three groups: (1) conventional mechanical ventilation (CV), (2) 
412 Open Lung Concept (OLC) started after arrival on the ICU and (3) OLC started directly after 
413 intubation. They observed an increase in functional residual capacity, reduced risk of hypoxemia 
414 and lower levels of IL-10 and IL-8 release, hence concluded that OLC ventilation leads to an 
415 attenuated inflammatory response, presumably by reducing additional lung injury after cardiac 
416 surgery [30]. 
417 A recent study was undertaken to examine the effect of maintaining ventilation during bypass 
418 compared with discontinued ventilation upon several parameters that may be indicative of lung 
419 injury. Twenty-three elective patients for CABG were randomised to either ventilation (VB) 
420 (n=12) or non-ventilation on bypass (NVB) (n=11). The post-bypass extravascular lung fluid was 
421 significantly smaller in the VB group compared to the NVB group and  extubation time was 
422 significantly shorter [31], hence this study has shown the benefits of maintaining ventilation 
423 during CPB on post-CPB oxygenation and included shorter mechanical ventilation [31].  On the 
424 other hand, a small study of fifty-nine patients prospectively randomised to continuous ventilation 
425 and no ventilation, during CABG on CPB, showed there was no statistically significant difference 
426 in most of inflammatory makers (IL-6, IL8, IL-10 & lactate) [32]. A recent metanalysis for 
427 patients undergoing cardiac su gery and received ventilation during CPB, included seventeen 
428 trials with 1162 patients, showed that ventilation during CPB significantly increased post-CPB 
429 PaO2/FiO2 ratio, but there was no sufficient evidence to show that ventilation during CPB could 
430 influence long-term prognosis of these patients [33].
431 The discordant conclusion from all previous studies on the effect of low frequency ventilation 
432 during CPB on lung function, was what prompted us to design and conduct this study. This is the 
433 first RCT to investigate the effects of low frequency ventilation in patients undergoing CABG 
434 with CPB by measuring inflammation directly in lung biopsies and blood samples.
435 Strengths and limitations
436 Our trial to the best of our knowledge is the first to report the effects of LFV on pulmonary 
437 inflammation in the blood and directly in lung biopsy in patients undergoing CABG with CPB. 
438 Random allocation was concealed, retention was good, data collection was blinded, and analyses 
439 were carried out and reported in accordance with a prespecified analysis plan. Therefore, the trial 
440 was at low risk of bias [34]. Although the sample size was small, there was no suggestion of any 
441 benefit from the adoption of LFV.
442 The surgical team could not be blinded, and we cannot rule out the possibility that this led to 
443 variations in surgical technique by group.  The use of PEEP in the intraoperative mechanical 
444 ventilation has been  associated with a reduction of atelectasis in postoperative period as reported 
445 by studies using high PEEP level (10 cm H2O) [35-37]. Overall the role of PEEP in surgery has 
446 been extensively studied with positive impression [33, 38-40]. In cardiac surgery particularly as 
447 the chest cavity is open, the lungs are arbitrarily exposed to atmospheric pressure, rather than 
448 normal negative intrathoracic pressure. Hence the transpulmonary pressure (airway pressure 
449 minus intrathoracic pressure) becomes abnormally low at end-expiration leading to collapse of the 
450 lungs, if we do not apply PEEP of at least 3-5 cm H2O. Nevertheless, in our treatment group we 
451 applied the LFV without PEEP. This is probably a major limitation that we could have avoided by 
452 adding PEEP to our LFV group.
































































454 Contrary to our working hypothesis low frequency ventilation (LFV) during CPB has not been 
455 demonstrated to reduce pulmonary or systemic inflammation compared to both lungs left 
456 collapsed and may in fact increase the levels of specific inflammatory cytokines. 
457
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466 Figure Legends
467 Figure 1. Consort diagram 
468
469
470 Figure 2a, b. Forest plot illustrating the treatment effect for each inflammatory marker.
471 a: in the lung tissue biopsies
472 b: in the blood samples 
473 Figure 3. Raw data on log scale (for y and x axis) [solid line=LFV, dash line=both lungs left 
474 collapsed] for p65, p38, ROS and HEME in blood
475
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Assessed for eligibility (n=49) 
Declined to participate (n=11) 
Randomised (n=38) 
Allocated to LFV (n=19) 
• Received LFV (n=18) 
• Did not receive LFV (had off-
pump CABG) (n=1) 
Allocated to “both lungs left 
collapsed” (n=19) 
• Received “both lungs left 
collapsed” (n=19) 
 
Analysed (n=18) Analysed (n=19) 






























































Figure 2 (a-b) 
a: forest plot illustrating the treatment effect for each inflammatory marker measured in the 
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LFV=Low frequency ventilation 

























<--- favours LFV      favours control --->

































































a) p65 in leukocytes and monocyets/granulocytes 
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Table 1 - Patient population characteristics and operative details
Variable* LFV (N=18) Lungs left collapsed (N=19)
Age (years) – mean (SD) 65.39 (12.09) 62.86 (10.08)
Height (m) - mean (SD) 1.70 (0.09) 1.69 (0.06)
Weight (kg) - mean (SD) 85.72 (15.49) 80.84 (15.29)
BMI (kg/m2) - mean (SD) 29.69 (4.14) 28.15 (4.82)
NYHA class – no. of patients (%) 
0 0 0
1 4 (22%) 9 (47%)
2 12 (67%) 9 (47%)
3 2 (11%) 1 (5%)
4 0 0
Left Ventricular Function – no. of patients (%)
Poor (<30%) 0 0
Moderate (30-50%) 4 (22%) 4 (21%)
Good (>50%) 14 (78%) 15 (79%)
Smoker/ex-smoker – no. of patients (%) 14 (78%) 12 (63%)
Asthma – no. of patients (%) 4 (22%) 0
COPD – no. of patients (%) 0 1 (5%)
Operation details
Bypass, minutes - median (IQR) 87.5 (68-97) 69 (54-79)
Cross-clamp, minutes - median (IQR) 44.5 (37-50) 35 (30-43)
Intubation, hours - median (IQR) 8.7 (7.1-10.3) 7 (6.4-10)
Time to discharge, days  - median (IQR) 6 (6-7) 6 (5-7)
*The median and interquantile range are reported for the variables whose distribution is skewed.






























































Table 2 - Adverse events
LFV n (%)
N=18
Lungs left collapsed (%)
N=19Adverse event
In hospital At follow up In hospital At follow up
Respiratory
Re-intubation/Ventilation 0 0 0 0
Mask CPAP 1 (5.6%) 0 2 (10.5%) 0
Tracheostomy 0 0 0 0
Prolonged ventilation (24 h) 0 0 0 0
ARDS 0 0 0 0
Pneumothorax / Effusion 0 0 0 0
Cardiovascular
MI 0 0 0 0
Cardiac arrest 0 0 0 0
Arrhythmias 9 (50%) 0 7 (36.8%) 0
Haemodynamic support 16 (89%) 0 9 (47.4%) 0
Neurological
Permanent Stroke 0 0 0 0
TIA 0 0 0 0
Renal
Hemofiltration / dialysis 0 0 0 0
Other 
GI complications 0 0 0 0
Thromboembolic complications 0 0 0 0
Bleeding complications 0 0 0 0
Wound complications 0 0 0 1 (5.3%)
Infective complications 4 (22.2%) 3 (17%) 4 (21.1%) 3 (15.8%)
Reoperation 0 0 0 0































































a) Comparison between LFV and both lungs left collapsed on lung tissue inflammatory markers 
LFV (N=18) Lungs left collapsed (N=18)Inflammatory 
Marker
Mean (SD)*
Before CPB Before chest 
closure
Before CPB Before chest 
closureNF-B p65 -1.92 (0.27) -1.86 (0.32) -1.87 (0.18) -1.91 (0.22)
p38 MAPK -1.12 (1.09) -1.19 (1.05) -1.26 (1.05) -1.08 (0.75)
TNF -7.36 (1.12) -6.91(0.73) -7.34(1.12) -7.33(0.86)
IL-1 -5.72(1.05) -3.15(1.13) -5.64(1.16) -4.10(1.17)
IL-18 -8.63(0.81) -8.67(0.56) -8.67(0.71) -8.42(1.09)
IL-6 -0.99(1.31) -6.12(1.10) -2.56(1.75) -6.03(0.87)
IP-10 -7.86(1.27) -7.54(1.24) -7.84(1.01) -7.66(1.33)
IL-8 -5.45(1.77) -1.30(1.39) -5.64(0.78) -2.30(1.72)
IL-10 -6.03(1.05) -5.03(2.30) -6.32(1.09) -5.26(1.63)
CXCR3 -4.22(1.77) -4.28(1.07) -4.59(1.95) -4.98(1.20)
Caspase 3 -2.46(0.38) -2.60(0.47) -2.56(0.60) -2.50(0.64)
   






























































 b) Comparison between LFV and both lungs left collapsed on blood inflammatory 
         markers with time fitted in the model






























































































































































































































































































































*Data are transformed because their distribution is not normal, the mean of the transformed data is 
tabulated.
**Negative data for ROS was set to missing. Most time points and cell type had only one value set to 
missing. ROS in Leukocyte at baseline and 2 hours had three missing values, ROS in Leukocyte at 6 
hours had 6 missing values.
***Monocytes overlapped with granulocytes for NF-B p65 and p38 MAPK
Table A2 
Summary of the main effects for primary and secondary endpoints in inflammatory markers 
(LFV vs Lungs left collapsed)




NF-B p65 0.102 -0.022  0.226    0.104
p38 MAPK -0.173 -0.723  0.376   0.525
TNF 0.425 -0.128  0.977     0.127
IL-1 0.985 0.228 1.742   0.012
IL-18 -0.310 -0.845  0.224    0.244






IP-10 0.251 -0.567  1.06    0.533






























































IL-8 0.995 -0.098  2.088    0.073
IL-10 -0.053 -1.244  1.138    0.929
CXCR3 0.551 -0.058   1.159    0.075
Caspase 3 0.186 -0.204   0.576    0.334
NF-B p65 leukocytes 0.023 -0.420   0.467    0.918
NF-B p65 monocytes_granulocyte -0.125 -0 .433   0.182    0.424
p38 MAPK leukocytes -0.146 -0 .524   0.232    0.448
p38 MAPK monocytes_granulocyte -0.029 -0.284   0.226    0.823
ROS monocytes -0.100 -0.353   0.152    0.436
ROS granulocyte -0.010 -0.196   0.176    0.913





Heme 0.142 -0.050   0.334    0.148
Results of the statistical inference summary showing the main effect for primary and 
secondary end points in standard care vs. LFV. Cytokines increased following surgery.  A 
positive value indicates that standard care was better than LFV whilst a negative value 
indicates an improved response to LFV.






























































Table A3 (a,b) 
a) Pulmonary gas exchange parameters (LFV vs Lungs left collapsed)
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b)  Lung function parameters (LFV vs Lungs left collapsed)
LFV Lungs left collapsedLung Function test
Mean(SD)* Pre-op Follow up Pre-op Follow up
FEV1 (% predicted) litres - mean (SD) 90.94 (21.58) 82.06 (19.86) 97.22 (18.83) 91 (20.20)
FVC (% predicted)  litres - mean (SD) 93.24 (20.73) 83.00 (18.37) 97.11 (18.51) 91.25 (16.55)
MEF75(% predicted)  litres/sec - mean (SD) 84.13 (42.32) 85.31 (39.01) 87.87 (30.83) 87.00 (30.37)
MEF25(% predicted)  litres/sec - mean (SD) 68.27 (36.25) 60.56 (25.77) 70.47 (25.82) 67.33 (23.94)
TLC(% predicted)  litres - mean (SD) 97.40 (14.53) 88.94 (11.76) 103.27 
(14.11)
90.08 (13.57)
RV (% predicted) litres - mean (SD) 112.73 
(25.60)
98.75 (24.47) 116.33 
(34.67)
95.17 (21.44)












FEV1(measured)  litres - mean (SD) 2.51 (0.91) 2.36 (0.81) 2.75 (0.81) 2.58 (0.89)
FVC(measured)   litres - mean (SD) 3.27 (1.07) 3.04 (0.99) 3.47 (0.95) 3.30 (0.99)
MEF75 (measured)  litres/sec - mean (SD) 5.40 (3.32) 5.87 (2.93) 5.93 (2.41) 6.09 (2.45)
MEF25 (measured)  litres/sec - mean (SD) 1.40 (2.02) 1.17 (1.57) 0.97 (0.51) 0.97 (0.55)
TLC(measured)   litres - mean (SD) 5.87 (1.19) 5.59 (1.07) 6.15 (1.07) 5.58 (1.16)
RV (measured)  litres - mean (SD) 2.57 (0.61) 2.29 (0.7) 2.61 (0.87) 2.17 (0.51)
TLCO(average)   (mmol/Kpa/min) - mean (SD) 7.63 (1.93) 7.29 (1.8) 7.53 (2.56) 6.69 (2.40)
KCO(average)   (mmol/Kpa/min) - mean (SD) 1.39 (0.26) 1.46 (0.25) 1.29 (0.19) 1.31 (0.27)
Percentage O2 saturation - mean (SD) 96.33 (1.05) 96.88 (1.58) 97.07 (1)
98 (0.85)
*If data are transformed because of the distribution is non-normal, then the mean of the 
transformed data will be tabulated.
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